These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
350 related articles for article (PubMed ID: 26824365)
1. Novel Therapeutic Approaches in Diabetes. Gallwitz B Endocr Dev; 2016; 31():43-56. PubMed ID: 26824365 [TBL] [Abstract][Full Text] [Related]
2. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction. Russell S Int J Clin Pharm; 2013 Apr; 35(2):159-72. PubMed ID: 23263796 [TBL] [Abstract][Full Text] [Related]
3. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797 [TBL] [Abstract][Full Text] [Related]
4. Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects. Drab SR Pharmacotherapy; 2010 Jun; 30(6):609-24. PubMed ID: 20500049 [TBL] [Abstract][Full Text] [Related]
5. GLP-1 receptor agonists or DPP-4 inhibitors: how to guide the clinician? Scheen AJ Ann Endocrinol (Paris); 2013 Dec; 74(5-6):515-22. PubMed ID: 23570814 [TBL] [Abstract][Full Text] [Related]
6. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. Neumiller JJ J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361 [TBL] [Abstract][Full Text] [Related]
7. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes. Cornell S J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069 [TBL] [Abstract][Full Text] [Related]
8. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors. Boland CL; Degeeter M; Nuzum DS; Tzefos M Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652 [TBL] [Abstract][Full Text] [Related]
9. Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials. Giugliano D; De Nicola L; Maiorino MI; Bellastella G; Esposito K Diabetes Obes Metab; 2019 Aug; 21(8):1790-1800. PubMed ID: 30969018 [TBL] [Abstract][Full Text] [Related]
10. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents. Blonde L; Montanya E Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():20-32. PubMed ID: 22405266 [TBL] [Abstract][Full Text] [Related]
12. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors. Gallwitz B Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567 [TBL] [Abstract][Full Text] [Related]
13. Impact of incretin therapy on islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes. McGill JB Postgrad Med; 2009 Jan; 121(1):46-58. PubMed ID: 19179813 [TBL] [Abstract][Full Text] [Related]
14. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors. Morales J Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467 [TBL] [Abstract][Full Text] [Related]
15. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes. Jellinger PS Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084 [TBL] [Abstract][Full Text] [Related]